In many cases, analysts are guilty of being overly optimistic about the near-term prospects of the stocks they cover. But sometimes they err in a completely opposite way.

Vertex Pharmaceuticals (NASDAQ: VRTX) looks like a good case in point. Wall Street thinks this stock will rise 12% over the next 12 months. Although that's not too shabby of a gain, here's why it could jump a lot more.

Let's first address why some on Wall Street don't have greater expectations for Vertex. One of the biggest factors is the biotech stock's previous success. Vertex's shares skyrocketed nearly 32% last year and are up close to 15% so far in 2023. There's skepticism as to how long this strong momentum can continue.

Continue reading

Source Fool.com